KURA — Kura Oncology, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1422143 ·
Last close
$10.61
Market Cap
$943.87M
52W High
$13.90
52W Low
$7.36
ADV30
2,185,506
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 20,874,000 | 20,631,000 | -73,010,000 | -68,327,000 | 587,791,000 | 70,242,000 | 539,360,000 |
| Mar 2026 | 18,265,000 | 18,003,000 | -78,815,000 | -73,333,000 | 652,551,000 | 39,083,000 | 544,668,000 |
| Dec 2025 | 17,336,000 | — | -86,268,000 | -80,999,000 | 738,363,000 | 149,099,000 | 564,228,000 |
| Sep 2025 | 20,750,000 | — | -79,997,000 | -74,116,000 | 649,381,000 | 95,287,000 | 406,839,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,985,000
Investing CF
$64,080,000
Financing CF
$1,719,000
CapEx
$-6,474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.35
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,247,421,000
Inventory
$843,000
Receivables
$9,348,000
ST Investments
$541,740,000
EBIT TTM
$-293,025,000
Pretax Income TTM
$-294,491,000
Interest Exp TTM
$1,466,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$77,225,000
EBITDA
$-316,799,008
Free Cash Flow
$-165,880,752
Enterprise Value
$518,691,456
Total Cash
$519,024,992
Total Debt
$24,455,000
Shares Out
88,960,619
Trailing EPS
$-3.37
Book Value
$0.54
ROE
-167.7%
ROA
-31.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,482,000 | -303,631,000 | -278,666,000 | 738,363,000 | 564,228,000 | 174,135,000 | -64,058,000 |
| Dec 2024 | 53,883,000 | -193,195,000 | -173,983,000 | 760,159,000 | 346,519,000 | 413,640,000 | 134,317,000 |
| Dec 2023 | 0 | -165,804,000 | -152,631,000 | 448,935,000 | 51,662,000 | 397,273,000 | -124,824,000 |
| Dec 2022 | 0 | -139,865,000 | -135,840,000 | 456,306,000 | 36,028,000 | 420,278,000 | -110,062,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.30
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.00 · spot: $10.61 · call volume: 1,423 · put volume: 1,160
Expected Move to 2027-04-16:
±$4.09
(38.55%) —
implied range
$6.52 –
$14.70
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBIOP | Fortress Biotech, Inc. | $936.35M | $16.52 | — |
| ALMS | ALUMIS INC. | $926.76M | $7.16 | — |
| ABUS | Arbutus Biopharma Corp | $962.79M | $4.86 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $922.04M | $49.36 | — |
| HELP | CYBIN INC. | $919.83M | $12.59 | — |
News headlines (Yahoo Finance, 1h cache)
Kura spins diabetes work into a Lilly-backed biotech startup
2026-09-09 15:54 · Yahoo
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
2026-09-09 11:00 · Yahoo
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
2026-09-08 11:00 · Yahoo
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run
2026-09-02 23:06 · Yahoo
Kura Oncology to Participate in Three Investor Conferences in September
2026-09-01 11:15 · Yahoo
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
2026-08-31 16:00 · Yahoo
Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase
2026-08-27 19:27 · Yahoo
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
2026-08-25 21:22 · Yahoo
The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today
2026-08-25 20:36 · Yahoo
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
2026-08-25 16:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.